Antibody, nature’s most magnificent molecule,
has come of age moving forward from an era of polyclonal and monoclonal
antibodies to its applications as functional antibody fragments or
modifications thereof for developing new drugs against vexing diseases, such
as, cancer and viral infections.
The conventional therapies against these
diseases have not been successful resulting in a shift towards development of
novel antibody-based therapeutics. The clinical success of antibodies can be assessed from their major commercial
impact as evidenced by the market for antibody drugs being over $60 billion in
2013, which is expected to double globally within the decade.
Current knowledge of the structure and
function of bovine antibodies provides important clues to strategically design
antibody-based drugs by optimized engineering.
No comments:
Post a Comment